A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

Trial Profile

A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Isotretinoin (Primary)
  • Indications Nodulocystic acne
  • Focus Registrational; Therapeutic Use
  • Sponsors Cipher Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2015 According to the Sun Pharma media release, based on the data of this trial NDA was approved for Absorica (Isotretinoin).
    • 19 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top